Syros Pharmaceuticals, Inc. - common stock (SYRS) Social Stream
SYROS PHARMACEUTICALS INC (SYRS) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering SYROS PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 5 | $23 | $9 | $17.2 | $2.82 | 509.93% |
| 2021-12-13 | 6 | $23 | $9 | $17.2 | $2.82 | 509.93% |
| 2022-01-03 | 6 | $23 | $9 | $17.6 | $2.82 | 524.11% |
| 2022-05-16 | 6 | $23 | $9 | $16 | $2.82 | 467.38% |
| 2022-05-17 | 6 | $23 | $9 | $14.333 | $2.82 | 408.26% |
| 2022-06-07 | 5 | $19 | $9 | $11.6 | $2.82 | 311.35% |
| 2022-08-09 | 5 | $19 | $6 | $10.8 | $2.82 | 282.98% |
| 2022-08-10 | 5 | $19 | $3 | $9.6 | $2.82 | 240.43% |
| 2022-09-12 | 4 | $19 | $3 | $9.6 | $2.82 | 240.43% |
| 2022-09-19 | 5 | $190 | $27 | $81.4 | $2.82 | 2786.52% |
| 2022-11-06 | 5 | $100 | $27 | $55.4 | $2.82 | 1864.54% |
| 2022-11-14 | 6 | $100 | $27 | $55.4 | $2.82 | 1864.54% |
| 2022-11-15 | 5 | $100 | $15 | $39.666 | $2.82 | 1306.6% |
| 2022-12-10 | 6 | $100 | $15 | $39.666 | $2.82 | 1306.6% |
| 2023-01-09 | 6 | $100 | $15 | $38.5 | $2.82 | 1265.25% |
| 2023-01-26 | 6 | $100 | $15 | $37.833 | $2.82 | 1241.6% |
| 2023-03-03 | 6 | $100 | $13 | $36.666 | $2.82 | 1200.21% |
The Trend in the Analyst Price Target
Over the past 29 weeks, SYRS's average price target has gone up $25.87.
SYRS reports an average of 1,920.65% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-09-12 | 5 | 19 | 3 | 9.600 | 7.303 | 31.45% |
| 2022-09-12 | 4 | 190 | 30 | 96.000 | 0.730 | 13050.68% |
| 2022-11-14 | 6 | 100 | 27 | 55.400 | 3.660 | 1413.66% |
| 2022-12-10 | 6 | 100 | 15 | 39.666 | 3.570 | 1011.09% |
| 2023-01-09 | 6 | 100 | 15 | 38.500 | 3.500 | 1000% |
SYRS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 15 months, SYRS's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how SYROS PHARMACEUTICALS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1877.49% of that group.
- To contextualize these metrics, consider that out of all US stocks, SYROS PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1743.73% of them.
- SYROS PHARMACEUTICALS INC's average analyst price target is greater than 1247.93% of stocks in the small market cap category.
- In terms of how SYROS PHARMACEUTICALS INC fares relative to stocks in the small market cap category, note that its number of analysts covering the stock is higher than 1309.06% of that group.
Stocks similar to SYROS PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CLSD, NOVN, and CRVS.
View All Top Stocks by Price Target
What is the outlook for SYRS? Use POWR Ratings for clearer insight into price direction.